Wieruszewski PM, Herasevich S, Gajic O, Yadav H. Respiratory failure in the hematopoietic stem cell transplant recipient. World J Crit Care Med 2018; 7(5): 62-72 [PMID: 30370228 DOI: 10.5492/wjccm.v7.i5.62]
Corresponding Author of This Article
Hemang Yadav, MBBS, MSc, Assistant Professor, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. yadav.hemang@mayo.edu
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Crit Care Med. Oct 16, 2018; 7(5): 62-72 Published online Oct 16, 2018. doi: 10.5492/wjccm.v7.i5.62
Respiratory failure in the hematopoietic stem cell transplant recipient
Patrick M Wieruszewski, Svetlana Herasevich, Ognjen Gajic, Hemang Yadav
Patrick M Wieruszewski, Department of Pharmacy, Mayo Clinic, Rochester, MN 55905, United States
Patrick M Wieruszewski, Svetlana Herasevich, Ognjen Gajic, Hemang Yadav, Multidisciplinary Epidemiology and Translational Research in Intensive Care Group, Mayo Clinic, Rochester, MN 55905, United States
Svetlana Herasevich, Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, United States
Ognjen Gajic, Hemang Yadav, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, United States
Author contributions: Wieruszewski PM generated the figures and wrote the manuscript; Herasevich S, Gajic O and Yadav H contributed to writing of the manuscript, provided intellectual contribution to the content, and made critical revisions; all authors reviewed and approved the final version of the manuscript.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hemang Yadav, MBBS, MSc, Assistant Professor, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. yadav.hemang@mayo.edu
Telephone: +1-507-2663958 Fax: +1-507-2664372
Received: August 2, 2018 Peer-review started: August 3, 2018 First decision: August 24, 2018 Revised: September 4, 2018 Accepted: October 10, 2018 Article in press: October 10, 2018 Published online: October 16, 2018 Processing time: 74 Days and 6.8 Hours
Abstract
The number of patients receiving hematopoietic stem cell transplantation (HSCT) is rapidly rising worldwide. Despite substantial improvements in peri-transplant care, pulmonary complications resulting in respiratory failure remain a major contributor to morbidity and mortality in the post-transplant period, and represent a major barrier to the overall success of HSCT. Infectious complications include pneumonia due to bacteria, viruses, and fungi, and most commonly occur during neutropenia in the early post-transplant period. Non-infectious complications include idiopathic pneumonia syndrome, peri-engraftment respiratory distress syndrome, diffuse alveolar hemorrhage, pulmonary veno-occlusive disease, delayed pulmonary toxicity syndrome, cryptogenic organizing pneumonia, bronchiolitis obliterans syndrome, and post-transplant lymphoproliferative disorder. These complications have distinct clinical features and risk factors, occur at differing times following transplant, and contribute to morbidity and mortality.
Core tip: Respiratory failure in the hematopoietic stem cell transplant recipient is common and is a major contributor of morbidity, mortality, and healthcare utilization. Etiology may be infectious or non-infectious in nature, and in some cases these may coexist. While identification remains challenging, infectious and non-infectious syndromes have distinct clinical features and risks.
